Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemoradiation for the Adjuvant Treatment of Adult Glioblastoma

NCT04552886 is registered in ClinicalTrials.gov with The Cooper Health System as lead sponsor.

NCT NCT04552886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04552886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemoradiation for the Adjuvant Treatment of Adult Glioblastoma
Lead sponsor
The Cooper Health System
Phase
Phase 1
Overall status
Completed
Start date
October 11, 2021
Completion date
December 1, 2023
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma